Sarah R Blumenthal1, Victor M Castro2, Caitlin C Clements1, Hannah R Rosenfield1, Shawn N Murphy2, Maurizio Fava3, Jeffrey B Weilburg3, Jane L Erb4, Susanne E Churchill5, Isaac S Kohane6, Jordan W Smoller7, Roy H Perlis1. 1. Center for Experimental Drugs and Diagnostics, Department of Psychiatry, Massachusetts General Hospital, Boston2Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry, Massachusetts General Hospital, Boston. 2. Partners Research Computing, Partners HealthCare System, Boston, Massachusetts4Laboratory of Computer Science, Department of Neurology, Massachusetts General Hospital, Boston. 3. Depression Clinic and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston. 4. Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts. 5. Information Systems, Partners HealthCare System, Boston, Massachusetts. 6. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 7. Psychiatric and Neurodevelopmental Genetics Unit, Department of Psychiatry, Massachusetts General Hospital, Boston.
Abstract
IMPORTANCE: Short-term studies suggest antidepressants are associated with modest weight gain but little is known about longer-term effects and differences between individual medications in general clinical populations. OBJECTIVE: To estimate weight gain associated with specific antidepressants over the 12 months following initial prescription in a large and diverse clinical population. DESIGN, SETTING, AND PARTICIPANTS: We identified 22,610 adult patients who began receiving a medication of interest with available weight data in a large New England health care system, including 2 academic medical centers and affiliated outpatient primary and specialty care clinics. We used electronic health records to extract prescribing data and recorded weights for any patient with an index antidepressant prescription including amitriptyline hydrochloride, bupropion hydrochloride, citalopram hydrobromide, duloxetine hydrochloride, escitalopram oxalate, fluoxetine hydrochloride, mirtazapine, nortriptyline hydrochloride, paroxetine hydrochloride, venlafaxine hydrochloride, and sertraline hydrochloride. As measures of assay sensitivity, additional index prescriptions examined included the antiasthma medication albuterol sulfate and the antiobesity medications orlistat, phentermine hydrochloride, and sibutramine hydrochloride. Mixed-effects models were used to estimate rate of weight change over 12 months in comparison with the reference antidepressant, citalopram. MAIN OUTCOME AND MEASURE: Clinician-recorded weight at 3-month intervals up to 12 months. RESULTS: Compared with citalopram, in models adjusted for sociodemographic and clinical features, significantly decreased rate of weight gain was observed among individuals treated with bupropion (β [SE]: -0.063 [0.027]; P = .02), amitriptyline (β [SE]: -0.081 [0.025]; P = .001), and nortriptyline (β [SE]: -0.147 [0.034]; P < .001). As anticipated, differences were less pronounced among individuals discontinuing treatment prior to 12 months. CONCLUSIONS AND RELEVANCE: Antidepressants differ modestly in their propensity to contribute to weight gain. Short-term investigations may be insufficient to characterize and differentiate this risk.
IMPORTANCE: Short-term studies suggest antidepressants are associated with modest weight gain but little is known about longer-term effects and differences between individual medications in general clinical populations. OBJECTIVE: To estimate weight gain associated with specific antidepressants over the 12 months following initial prescription in a large and diverse clinical population. DESIGN, SETTING, AND PARTICIPANTS: We identified 22,610 adult patients who began receiving a medication of interest with available weight data in a large New England health care system, including 2 academic medical centers and affiliated outpatient primary and specialty care clinics. We used electronic health records to extract prescribing data and recorded weights for any patient with an index antidepressant prescription including amitriptyline hydrochloride, bupropion hydrochloride, citalopram hydrobromide, duloxetine hydrochloride, escitalopram oxalate, fluoxetine hydrochloride, mirtazapine, nortriptyline hydrochloride, paroxetine hydrochloride, venlafaxine hydrochloride, and sertraline hydrochloride. As measures of assay sensitivity, additional index prescriptions examined included the antiasthma medication albuterol sulfate and the antiobesity medications orlistat, phentermine hydrochloride, and sibutramine hydrochloride. Mixed-effects models were used to estimate rate of weight change over 12 months in comparison with the reference antidepressant, citalopram. MAIN OUTCOME AND MEASURE: Clinician-recorded weight at 3-month intervals up to 12 months. RESULTS: Compared with citalopram, in models adjusted for sociodemographic and clinical features, significantly decreased rate of weight gain was observed among individuals treated with bupropion (β [SE]: -0.063 [0.027]; P = .02), amitriptyline (β [SE]: -0.081 [0.025]; P = .001), and nortriptyline (β [SE]: -0.147 [0.034]; P < .001). As anticipated, differences were less pronounced among individuals discontinuing treatment prior to 12 months. CONCLUSIONS AND RELEVANCE: Antidepressants differ modestly in their propensity to contribute to weight gain. Short-term investigations may be insufficient to characterize and differentiate this risk.
Authors: Floris Imhann; Arnau Vich Vila; Marc Jan Bonder; Ailine G Lopez Manosalva; Debby P Y Koonen; Jingyuan Fu; Cisca Wijmenga; Alexandra Zhernakova; Rinse K Weersma Journal: Gut Microbes Date: 2017-01-24
Authors: Brian S Schwartz; Thomas A Glass; Jonathan Pollak; Annemarie G Hirsch; Lisa Bailey-Davis; Timothy H Moran; Karen Bandeen-Roche Journal: Obesity (Silver Spring) Date: 2016-11-02 Impact factor: 5.002
Authors: Lara C Weinstein; Ana Stefancic; Amy T Cunningham; Katelyn E Hurley; Leopodo J Cabassa; Richard C Wender Journal: CA Cancer J Clin Date: 2015-12-10 Impact factor: 508.702